Novel Agents Under Investigation for Multiple Myeloma

An expert panel highlights novel therapeutic approaches for newly diagnosed and relapsed multiple myeloma.

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

Experts from the Mayo Clinic and Moffitt Cancer Center go head-to-head to discuss recent data in multiple myeloma and updates from recent meetings.

CancerNetwork®’s podcast dives into an article focused on treatment options for older, transplant-ineligible patients with multiple myeloma.

The FDA and European Medicines Agency accept applications for elranatamab for relapsed or refractory multiple myeloma.

The investigational CAR T-cell therapy equecabtagene autoleucel receives fast track and regenerative medicine advanced therapy designations for managing relapsed or refractory multiple myeloma.